Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial
W. van Gijn, Corrie A.M. Marijnen, Irıs D. Nagtegaal et al. · The Lancet Oncology · 2011
Cited by 1,892 works. doi:10.1016/s1470-2045(11)70097-3
Authors
- W. van Gijn
- Corrie A.M. Marijnen
- Irıs D. Nagtegaal
- Elma Meershoek‐Klein Kranenbarg
- Hein Putter
- Theo Wiggers
- Harm J. T. Rutten
- Lars Påhlman
- Bengt L. G. Glimelius
- Cornelis JH van de Velde
References
- Proportional Hazards Tests and Diagnostics Based on Weighted Residuals
- Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer
- LOCAL RECURRENCE OF RECTAL ADENOCARCINOMA DUE TO INADEQUATE SURGICAL RESECTION
- Mesorectal excision for rectal cancer
- Improved Survival with Preoperative Radiotherapy in Resectable Rectal Cancer
- A prospective randomized trial
- The Stockholm I trial of preoperative short term radiotherapy in operable rectal carcinoma
- Pre- or Postoperative Radiotherapy in Rectal and Rectosigmoid Carcinoma Report from a Randomized Multicenter Trial
- Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial
- The TME Trial After a Median Follow-up of 6 Years